2 -12 (74) 2024 - Sayfutdinov Z.A. - MICROBIOLOGICAL FEATURES OF THE COURSE OF WIDESPREAD DRUG-RESISTANT PULMONARY TUBERCULOSIS

MICROBIOLOGICAL FEATURES OF THE COURSE OF WIDESPREAD DRUG-RESISTANT PULMONARY TUBERCULOSIS

Sayfutdinov Z.A. - Center for the Development of Professional Qualifications of Medical Workers under the Ministry of Health of the Republic of Uzbekistan

Resume

The massiveness of bacterial excretion in pulmonary tuberculosis is an indirect indicator reflecting the cavity character of changes in lung tissue and the density of the bacterial population. A prospective examination of 135 patients with extensively drug-resistant (XDR) pulmonary tuberculosis was conducted. The study included 68 men (45.8%) and 147 women (67%) aged 18 to 65 years. The bacteriological characteristics of XDR-TB of the lungs in the group of previously treated patients were significantly more pronounced in most parameters.

Key words: microbiological features, drug resistance, pulmonary tuberculosis.

First page

11

Last page

15

For citation:Sayfutdinov Z.A. - MICROBIOLOGICAL FEATURES OF THE COURSE OF WIDESPREAD DRUG-RESISTANT PULMONARY TUBERCULOSIS//New Day in Medicine 12(74)2024 11-15 https://https://newdayworldmedicine.com/en/new_day_medicine/12-74-2024

List of References

1. Абдуллаев Р.Ю. Гепатотоксические реакции при лечении впервые выявленных больных туберкулезом легких с множественной лекарственной устойчивостью возбудителя / Р.Ю. Абдуллаев, О.Г. Комиссарова, Е.С. Чумакова [и др.] //Туберкулез и болезни легких. 2019;97(7):21-27.
2. Барканова О.Н. Туберкулез легких с множественной лекарственной устойчивостью возбудителя //Заметки ученого. 2015;6(1):19-21.
3. Кузьмина Н.В. Течение и эффективность лечения туберкулеза с множественной и широкой лекарственной устойчивостью / Н.В. Кузьмина, Н.В. Нелидова, Ю.А. Шкарпеткин [и др.] // Фундаментальные и прикладные проблемы здоровьесбережения человека на Севере: Сборник материалов V Всероссийской научно-практической конференции, Сургут, 27 октября 2020 года. – Сургут: Сургутский государственный университет, 2020; 82-88 с.
4. Kranzer K. New WHO Treatment Recommendations for Multidrug-Resistant Tuberculosis: Are We Well Enough Prepared? //Am J Respir Crit Care Med. 2019; Apr 26. [Epub ahead of print].
5. Vjecha M.J. Accelerating the development of therapeutic strategies for drug‐resistant tuberculosis //Nat Rev Drug Discov. 2018;17(9):607-608.
6. World Health Organization. WHO consolidated guidelines on drug-resistant tuberculosis treatment. Geneva, World Health Organization, 2020.
7. Zhao Y. Improved treatment outcomes with bedaquiline when substituted for second-line injectable agents in multidrug resistant tuberculosis: a retrospective cohort study //Clin Infect Dis 2018.

   file

   download